MTOR and cancer: These ATP-binding inhibitors were termed “second-generation mTOR inhibitors,” also known as “TORKinib” or “TORKi.” These concurrent mTORC1 and mTORC2 inhibitors have effectively targeted the proliferation and self-renewal of GBM cancer stem cells.